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The preliminary results of this investigation were presented on April 24th, 2014 during the Great Lakes 
Pharmacy Resident Conference in West Lafayette, Indiana. 
 
Abstract 
Study objective: Although rabbit anti-thymocyte globulin (rATG) is commonly used as induction therapy 
for kidney transplantation, dosing is not standardized. Recently available findings suggest that even 
subtle differences in the cumulative dose of rATG induction may impact acute rejection rates for 
patients receiving steroid minimization maintenance immunosuppression. This investigation evaluated 
the potential consequences of rounding and capping rATG doses in patients receiving steroid-containing 
maintenance immunosuppression when calculating the dose based on actual body weight. 
Design: Single-center, retrospective, cohort study. 
Setting: A large academic medical center. 
Patients: Two hundred and sixty one adult kidney transplant recipients between July 1, 2010 and 
December 31, 2012 who received rATG induction and were maintained on tacrolimus, mycophenolate 
and prednisone. 
Methods and Measurements: Incidences of biopsy-confirmed acute rejection, opportunistic infections 
and hematologic effects within 12 months post-transplant were assessed for patients receiving a 
cumulative rATG dose ≥ 5 mg/kg (5.2 ± 0.2 mg/kg, n = 138) compared to those who received a 
cumulative rATG dose < 5 mg/kg (4.5 ± 0.6 mg/kg, n = 123). The groups had similar baseline 
characteristics, immunologic risk, and indications for rATG induction. The incidence of clinically relevant 
biopsy-confirmed acute rejection was low and similar between the groups (8.7% for rATG ≥ 5 mg/kg vs 
8.9% for rATG < 5 mg/kg, P = 0.944). Patient survival, all-cause graft survival, and graft function did not 
differ between the groups. Incidences of cytomegalovirus and BK virus infection as well as the extent 
and duration of lymphopenia were also similar between the groups.  
Conclusions: In combination with triple maintenance immunosuppression consisting of tacrolimus, 
mycophenolate, and prednisone, modest differences in the cumulative rATG dose were not associated 
with increased risk of acute rejection. Measures to optimize rATG utilization present opportunities for 
cost-saving without sacrificing efficacy in this patient population.  
 
Introduction 
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Despite having U.S. Food and Drug Administration approval only for the treatment of acute rejection, 
rabbit anti-thymocyte globulin (rATG) is commonly used for induction immunosuppression in solid organ 
transplantation.  Approximately half of adult kidney transplant recipients in the United States receive 
rATG for induction1.  rATG induction has been compared to placebo, equine anti-thymocyte globulin, 
and an interleukin-2 receptor antagonist in prospective, randomized, controlled clinical trials2-4.  
Cumulative rATG induction doses of 7.5-12.5 mg/kg resulted in significantly decreased acute rejection 
rates at the potential expense of prolonged lymphocyte depletion and increased risk of opportunistic 
infections2-4.  Subsequent investigations have reported that cumulative rATG doses as low as 4.5-7.5 
mg/kg could be effective for induction in combination with triple immunosuppression regimens 
including a calcineurin inhibitor, an antiproliferative agent, and corticosteroids5-7.  However, a recent 
investigation found that cumulative rATG doses of 5-6 mg/kg were associated with an increased acute 
rejection rate compared to cumulative doses of at least 6 mg/kg (21% vs. 11%, P < 0.0418) when 
combined with steroid- avoidance maintenance immunosuppression8.  
At the University of Michigan, a cumulative rATG dose of 5 mg/kg based on actual body weight 
is used for induction therapy. However, doses are rounded to the nearest vial size and capped at a total 
of 500 mg, which can result in administration of a cumulative dose < 5 mg/kg, especially for overweight 
patients.  The absence of randomized controlled trials and contradictions in the available data 
emphasize the need for additional information to determine the optimal dose of rATG for induction in 
kidney transplantation, particularly when used in combination with triple immunosuppressive 
maintenance regimens.  Therefore, this study was designed to assess effectiveness and toxicity 
outcomes associated with subtle differences in cumulative dose of rATG induction in patients receiving 
steroid-containing maintenance immunosuppression.  
 
Materials and Methods 
This retrospective, single-center, cohort study included adult kidney transplant patients that received a 
living or deceased donor graft at the University of Michigan between July 1, 2010 and December 31, 
2012.  All included patients received rATG induction and were maintained on tacrolimus, 
mycophenolate, and prednisone.  According to the institutional protocol, indications for rATG induction 
included African-American race, living unrelated kidney transplant (LUKT), panel reactive antibody (PRA) 
> 20%, presence of donor specific antibody (DSA), and marginal graft function within 24 hours post-
transplant defined as urine output < 0.5 mL/kg/hour, a decline in serum creatinine < 10% from pre-
transplant baseline, or a need for hemodialysis.  Patients who received a prior or simultaneous non-
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renal transplant, underwent desensitization, experienced primary graft non-function, expired within 7 
days of transplantation, and those who received a positive crossmatch graft, investigational 
medications, or rATG for non-protocol indications were excluded.  Eligible patients were divided into 
two groups: those who received a cumulative rATG dose of ≥ 5 mg/kg (Group I) and those who received 
< 5 mg/kg (Group II) based on pre-operative actual body weight. 
Induction with rATG consisted of 1.5 mg/kg on post-operative day (POD) 0 and POD 1, followed 
by 2 mg/kg on POD 2, for a cumulative dose of 5 mg/kg.  Doses were rounded to the nearest vial size (25 
mg) and capped at 150 mg for 1.5 mg/kg on POD 0 and POD 1 and 200 mg for 2 mg/kg on POD 2.  Dose 
alterations were not allowed for patients with leukopenia or thrombocytopenia.  In patients with 
marginal graft function, rATG induction was initiated post-operatively upon assessment of urine output 
and serum creatinine.  For the other indications, the first dose of rATG was given intra-operatively 
before reperfusion of the kidney graft.  Corticosteroids were administered according to the following 
schedule: methylprednisolone IV 500 mg intra-operatively followed by oral prednisone starting at 100 
mg on POD 1 with gradual taper to 10 mg by POD 30.  Further reduction of prednisone to 5 mg was done 
at the discretion of the transplant nephrologist.  Tacrolimus 0.05 mg/kg PO every 12 hours was initiated 
within 24 hours of transplantation with trough targets of 8-12 ng/mL for POD 0-90, 6-10 ng/mL for POD 
91-120 and 4-8 ng/mL beyond POD 121.  Mycophenolate mofetil 1000 mg PO every 12 hours was 
initiated on POD 0.  All patients received prophylaxis for fungal infection (nystatin suspension) and 
Pneumocystis jirovecii infection (trimethoprim/sulfamethoxazole or inhaled pentamidine) for 1 month.  
Patients at risk for cytomegalovirus (CMV) infection received antiviral prophylaxis with valganciclovir 
according to the institutional protocol. 
The primary endpoint was incidence of biopsy-confirmed acute rejection (BCAR) grade 1A or 
greater within 12 months post-transplant as determined by Banff histologic criteria9.  Secondary 
outcomes included incidences of CMV, BK viremia (BKV) and BK virus nephropathy (BKVN), patient and 
graft survival, graft function assessed by serum creatinine at 12 months, and hematologic effects 
including leukopenia, thrombocytopenia, and lymphopenia. Per protocol, BKV screening by PCR occurs 
at 1, 2, 3, 6, 9, and 12 months post-transplant. CMV PCR was performed in conjunction with signs and 
symptoms suggestive of CMV infection. Student’s unpaired t-test and one-way ANOVA were used to 
compare continuous variables.  Categorical variables were compared using the chi-square test. All 
statistical analyses were performed using SPSS 21 (IBM, Armonk, NY). This investigation was approved 
by the University of Michigan Institutional Review Board.  
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Results 
Among 474 kidney transplants performed between July 1, 2010 and December 31, 2012,  261 were 
included in the final analysis (Figure 1).  With the exceptions of weight and body mass index (BMI), the 
groups were well-matched with respect to demographics and immunologic risk factors (Table 1).  The 
average rATG dose in Group I was 5.2 ± 0.2 mg/kg compared with 4.5 ± 0.6 mg/kg for Group II (P < 
0.001), and no patient received more than 6 mg/kg of rATG.  Two patients in Group II did not complete 
all three doses of rATG due to intolerance (respiratory distress and rash for one patient and hypotension 
for the other patient); these patients received single doses of 1.3 and 1.4 mg/kg, respectively.  
Tacrolimus trough concentrations in the first week post-transplant were similar.  All patients were 
maintained on a steroid-containing regimen and the majority continued the triple maintenance 
immunosuppression through 12 months (Table 2). There were no differences in the distribution of 
indications for rATG induction (Table 3). The 24 patients who received rATG for marginal graft function 
did not have another indication for induction, and therefore received only steroids intra-operatively 
(Group I, 8.7% vs. Group II, 9.8%; P = 0.767). The overall incidence of marginal graft function was 31% 
and did not differ between the groups (Group I, 31% vs. Group II, 31%; P = 0.963).   
Patient and graft outcomes did not differ significantly between the groups. At 12 months post-
transplant, 98.6% of patients in Group I were alive compared with 98.4% in Group II (P = 0.908).  All-
cause graft survival was 95.7% in Group I and 97.6% for Group II (P = 0.399). Graft function as measured 
by serum creatinine at 12 months was also similar (Group I, 1.4 ± 0.7 mg/dL vs. Group II, 1.5 ± 1.0 mg/dL; 
P = 0.583).No significant differences in the primary endpoint of BCAR ≥ 1A, recurrent BCAR, or antibody-
mediated rejection were observed (Table 4).  Similarly, no significant difference in BCAR ≥ 1A was found 
when patients were stratified based on BMI (Table 5).  Cumulative rATG dose was not associated with a 
difference in time to BCAR ≥ 1A within the first 12 months (Figure 2).   
Regarding the toxicity-related outcomes, no differences in CMV (Group I, 8.0 % vs. Group II, 
9.8%; P = 0.385), BKV (Group I, 10.9% vs. Group II, 10.6%; P = 0.550) or BKVN (Group I, 4.3% vs. Group II, 
4.1%; P = 0.579) were observed.  The incidences of lymphopenia, thrombocytopenia, and leukopenia did 
not differ significantly between the groups (Figure 3).  rATG induction depleted circulating lymphocytes 
to < 500 cells/mm3 and lymphocyte depletion was sustained until POD 90 in almost 40% of patients.  The 
degree and duration of lymphopenia was not different between the groups.   
 
Discussion 
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The rATG induction dose that provides adequate protection from acute rejection with minimal 
hematologic and infectious complications is a subject of ongoing investigation.  This investigation 
provided additional evidence regarding weight-based dosing strategies for rATG induction in adult 
kidney transplant recipients with immunologic risk factors.  In our cohort, rATG induction at a 
cumulative dose of 5 mg/kg given in combination with tacrolimus-based steroid-containing triple 
maintenance immunosuppression was effective in preventing acute rejection.  The overall incidence of 
12-month BCAR was lower than 9% and the small difference in rATG dose due to rounding and capping 
did not appear to have a significant impact on the rejection rate.  The difference in rATG dose was not 
associated with changes in opportunistic infections, hematologic toxicities or duration of lymphopenia. 
Previous studies using various rATG doses in combination with triple maintenance 
immunosuppression regimens consisting of a calcineurin inhibitor, an antiproliferative agent, and 
steroids reported similar acute rejection rates to those in the current study.  One study reported that 
rATG doses were commonly halved or held for leukopenia or thrombocytopenia when a cumulative 
dose of 10.5 mg/kg was given over a 7-day course5.  Therefore, they compared this historical control 
group to patients receiving a reduced cumulative dose of 6 mg/kg over a 3-day course and found no 
significant difference in BCAR at 12 months (4.2% for 10.5 mg/kg vs. 5% for 6 mg/kg, P = 1.0).  
Additionally, the patients receiving 6 mg/kg had a significantly shorter length of stay than those 
receiving 10.5 mg/kg (6 vs. 8 days, P = 0.002).  A different study in adult kidney transplant patients 
reported that the incidence of BCAR at 12 months was similar (9.5% for > 7.5 mg/kg vs. 8.8% for ≤ 7.5 
mg/kg, P = 0.9) between patients who received a target cumulative rATG dose of 7.5 mg/kg (10.3 ± 2.1 
mg/kg) and those who received ≤ 7.5 mg/kg, (5.7 ± 1.6 mg/kg)6.  Another investigation comparing lower 
cumulative doses of 6 mg/kg given over 4 days and 4.5 mg/kg given over 3 days also reported no 
significant difference in acute rejection rates at 12 months (11% for 6 mg/kg vs. 10% for 4.5 mg/kg, P = 
1.0)7.  The median length of stay was significantly shorter for the patients receiving the 3-day regimen (3 
vs. 4 days, P = 0.004).  These studies provided the foundation for the 3-day rATG induction dosing 
strategy at our center.   
A more recent rATG induction dosing investigation observed an increase in acute rejection with 
cumulative doses of 5-6 mg/kg, raising concern particularly for centers targeting total doses in this 
range8.  In contrast to these findings, which evaluated different cumulative rATG doses administered in 
combination with a steroid avoidance maintenance regimen, the results presented in our study align 
with prior rATG induction dosing investigations using similar triple maintenance immunosuppression. 
Our findings also address the uncertainty regarding potential consequences of underdosing rATG in 
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overweight patients.  The absence of any clinically significant difference in both safety and efficacy 
between average doses of 4.5 mg/kg compared to 5.2 mg/kg provides reassurance for the use of doses 
in this range, which are known to cause fewer adverse events and may offer cost- saving advantages as 
well.  
We have observed variations in the weight used for rATG dose calculation.  In most patients, 
pre-operative weight was used to determine all three doses of rATG.  Weight often increased post-
operatively due to fluid overload, so that higher doses of rATG were given when actual body weight on 
the day of rATG administration was used for the dose calculation.  Our findings suggest that modest 
variation in rATG induction dosing due to rounding and capping may not significantly compromise short-
term outcomes, provided that patients receive approximately 5 mg/kg based on pre-operative actual 
body weight.  During the 30-month period of this investigation, a total of 104,800 grams of rATG were 
administered to 261 patients.  If all doses were based on pre-operative actual body weight, only 103,225 
grams of rATG would have been needed.  Standardizing the dosing weight could reduce rATG utilization 
by 1,575 grams over 30 months.  At a wholesale acquisition cost of $664.46/25 gram vial10, dosing rATG 
based on the pre-operative weight rather than the current weight translates to an annual cost savings of 
$6,415 per 100 patients.   
This investigation is limited by the retrospective, non-randomized, single-center design.  
Confounders such as adherence to maintenance immunosuppression regimen or mycophenolate dose 
adjustment were not captured.  Although there was no difference in the average tacrolimus levels 
during the first week post-transplant, the exposure to tacrolimus preceding any episodes of rejection is 
unknown.  Because no patient in our study cohort received a cumulative rATG dose > 6 mg/kg, any 
differences that exist with higher doses could not be detected.  
Dividing patients based on the cumulative rATG dose also assigned those with higher BMI to 
Group II (< 5 mg/kg).  Obesity is characterized as a chronic inflammatory condition during which 
adipocytes produce pro-inflammatory cytokines that promote T-cell proliferation11.  Therefore, obese 
patients may have an inherently increased risk of rejection.  A national registry data analysis identified 
27,377 kidney transplant recipients with complete anthropometric data available in the national 
registry12. When compared with  patients who had a normal BMI (18.5-24.9 kg/m2), obese patients (BMI 
30-34.9 kg/m2) were more likely to experience acute rejection before discharge (OR [95% CI], 1.19 [1.04-
1.36]) and morbidly obese patients (BMI ≥ 35 kg/m2) were more likely to experience acute rejection 
prior to discharge and at 6  and 12  months post-transplant (OR [95% CI], 1.5 [1.3-1.86], 1.28 [1.11-1.49], 
and 1.2 [1.09-1.55], respectively).  A single-center observational study of 1151 kidney transplant 
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recipients found an increased risk of acute rejection for patients in the highest BMI strata (≥ 35 kg/m2) 
compared with  those who had a  BMI 20-24.9 kg/m2 (HR [95% CI], 2.19 [1.37-3.49])13.  However, these 
findings have not been reproduced consistently in other studies.  A meta-analysis that included 11 
studies representing 3,307 patients found no association between obesity and acute rejection (RR [95% 
CI], 0.95 [0.82-1.11])14.  Our study included 47 patients with a BMI in the range previously associated 
with increased risk of rejection (≥ 35 kg/m2), and these patients received a lower dose of rATG 
compared to those with a BMI < 35 kg/m2.  We did not observe any differences in BCAR when patients 
were stratified by BMI (Table 5).  
Although the recipients at highest immunologic risk were excluded, including those who were 
ABO incompatible, positive crossmatch, and those receiving desensitization or steroid avoidance, our 
study population was diverse and included highly sensitized patients as well as those with multiple 
immunologic risk factors (Table 3). The results of this investigation suggest that modest differences in 
rATG induction dose are not associated with increased risk of acute rejection when a cumulative dose of 
5 mg/kg is targeted in combination with triple maintenance immunosuppression.  Therefore, it is 
reasonable to determine the rATG dose based on actual body weight with rounding and capping in this 
patient population in order to minimize toxicity as well as cost.  
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Table 1. Baseline characteristics 
 Group I (n = 138) Group II (n = 123) P-value 
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ABW = actual body weight, BMI = body mass index, CMV = cytomegalovirus, DDKT = deceased donor 
kidney transplant, DM = diabetes mellitus, DSA = donor specific antibody, FSGS = focal segmental 
glomerulosclerosis, GN = glomerulonephritis, HTN = hypertension, IBW = ideal body weight, LRKT = living 
related kidney transplant, LUKT = living unrelated kidney transplant, PCKD = polycystic kidney disease, 
PRA = panel reactive antibody, SD = standard deviation 
 
 
 
Age (years), mean ± SD 50.3 ± 14.1 50.5 ± 11.9 0.918 
Male, n (%) 82 (59.4) 76 (61.8) 0.696 
ABW (kg), mean ± SD 80.3 ± 13.8 94.6 ± 24.4 < 0.001 
IBW (kg), mean ± SD 64.4 ± 11.5 66.8 ± 10.9 0.084 
BMI (kg/m2), mean ± SD 27.6 ± 4.8 31.3 ± 6.9 < 0.001 
Follow up (days), mean ± SD 661 ± 263 717 ±260 0.087 
Indication for transplant, n (%) 
HTN 
DM 
HTN and DM 
PCKD 
GN 
FSGS 
Other 
 
28 (20.3) 
28 (20.3) 
15 (10.9) 
10 (7.2) 
16 (11.6) 
10 (7.2) 
31 (22.5) 
 
25 (20.3) 
26 (21.1) 
14 (11.4) 
14 (11.4) 
19 (15.4) 
8 (6.5) 
17 (13.8) 
0.588 
Donor, n (%) 
DDKT 
LRKT 
LUKT 
 
84 (61.9) 
8 (5.8) 
46 (33.3) 
 
63 (51.2) 
13 (10.6) 
47 (38.2) 
0.187 
African American, n (%) 46 (33.3) 33 (26.8) 0.282 
PRA > 20%, n (%) 57 (41.3) 49 (39.8) 0.810 
DSA, n (%) 26 (18.1) 26 (21.1) 0.643 
Retransplantation, n (%) 14 (17.4) 16 (13.0) 0.326 
CMV high-risk (donor +/recipient -), n (%) 33 (23.9) 28 (22.8) 0.884 
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Table 2. Maintenance immunosuppression 
 Group I (n = 138) Group II (n = 123) P-value 
Mean tacrolimus level on POD 3-7 
(ng/mL), mean ± SE 
8.8 ± 4.8 9.1 ± 4.2 0.573 
Mean tacrolimus level on POD3-7 ≥ 8 
ng/mL, n (%) 
72 (52.2) 68 (55.3) 0.615 
Immunosuppression at 12 months 
    TMP, n (%) 
    TP, n (%) 
    mTOR, n (%) 
    Other, n (%) 
 
124 (89.9) 
10 (7.2) 
3 (2.2) 
1 (0.7) 
 
114 (92.7) 
6 (4.9) 
2 (1.6) 
1 (0.8) 
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mTOR = any regimen containing everolimus or sirolimus, POD = post-operative day, SE = standard error, 
TMP = tacrolimus, mycophenolate and prednisone, TP = tacrolimus and prednisone 
 
 
Table 3. Indications for rabbit anti-thymocyte globulin induction 
 Group I (n = 138) Group II (n = 123) P-value 
African-American, n (%) 46 (33.3) 33 (26.8) 0.282 
LUKT, n (%) 46 (33.3) 47 (38.2) 0.411 
PRA > 20%, n (%) 57 (41.3) 49 (39.8) 0.810 
DSA, n (%) 26 (18.1) 26 (21.1) 0.643 
Number of indications 
Two, n (%) 
Three, n (%) 
 
30 (21.7) 
10 (7.2) 
 
30 (24.4) 
5 (4.1) 
0.510 
Marginal graft function only, n (%)* 12 (8.7) 12 (9.8) 0.927 
 
*Patients without other indications who developed marginal graft function received the first dose of 
rabbit anti-thymocyte globulin (rATG) post-operatively.  For the other patients, rATG was initiated intra-
operatively.   
DSA = donor specific antibody, LUKT = living unrelated kidney transplant, PRA = panel reactive antibody 
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Table 4. Biopsy-confirmed acute rejection at 12 months 
 Group I (n = 138) Group II (n = 123) P-value 
BCAR grade ≥ 1A, n (%) 12 (8.7) 11 (8.9) 0.994 
BCAR grade    
BCAR grade 1, n (%) 6 (4.3) 9 (7.3) 0.304 
BCAR grade 2, n (%) 5 (3.6) 1 (0.8) 0.130 
BCAR grade 3, n (%) 1 (0.7) 1 (0.8) 0.935 
Recurrent BCAR grade ≥ 1A, n (%) 10 (7.2) 3 (2.4) 0.075 
Antibody-mediated rejection, n (%) 5 (3.6) 2 (1.6) 0.319 
 
BCAR = biopsy-confirmed acute rejection 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Biopsy-confirmed acute rejection stratified by body mass index  
 BMI ≤ 24.9 
kg/m2 (n = 68) 
BMI 25 - 29.9 
kg/m2 (n = 81) 
BMI 30 - 34.9 
kg/m2 (n = 65) 
BMI ≥ 35 
kg/m2 (n = 47) 
P-value 
BCAR grade ≥ 1A, 
n (%) 
5 (7.4) 7 (8.6) 9 (13.8) 2 (4.3) 0.328 
rATG dose 5.0 ± 0.5 5.0 ± 0.2 4.9 ± 0.5 4.4 ± 0.6 < 0.001 
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(mg/kg), mean ± 
SD 
  
BCAR = biopsy-confirmed acute rejection, BMI = body mass index, rATG = rabbit anti-thymocyte globulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure legends 
Figure 1. Study population 
Figure 2. Kaplan-Meier graph illustrating overall rejection-free survival according to rabbit anti-
thymocyte globulin induction dose (Group I ≥ 5 mg/kg and Group II < 5 mg/kg).  Time to event includes 
time to an episode of BCAR ≥ 1A, graft loss, or death--whichever occurred earlier.  
Figure 3. Hematologic effects of rabbit anti-thymocyte globulin induction following transplant (Group I ≥ 
5 mg/kg and Group II < 5 mg/kg): (a) absolute lymphocyte counts, (b) total white blood cell counts, (c) 
platelet counts and (d) patients with absolute lymphocyte counts below 500 cells/mm3.  
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